Please note: The information displayed on this page might be outdated.
Nouscom AG: Nouscom is a next-generation immunotherapy company developing genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. The company has offices in Basel and Rome.
Company Participants at European Biotech Investor Days 2021
Nouscom AG, CBO
Richard (Rick) Davis is an accomplished executive with more than 20 years' experience in the life sciences sector with a focus on developing and building strategic partnerships and growth strategies. Prior to joining Nouscom, he was Global Oncology Transactor at Johnson & Johnson Innovation. Previously, Dr. Davis held executive roles in both private and public European biotech companies and has been responsible for maximizing financial returns on direct healthcare investments in both private and public equities and venture capital funds at the Wellcome Trust. During this time, he was on the Board of Directors of a number of biotech companies and worked closely with management teams on strategy, financing and exits via M&A and public listings.